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International incidence and 
mortality trends of liver cancer: a 
global profile
Martin C. S. Wong1,2, Johnny Y. Jiang3, William B Goggins1, Miaoyin Liang1, Yuan Fang1, 
Franklin D. H. Fung1, Colette Leung1, Harry H. X. Wang4,5, Grace L. H. Wong2,6,7, 
Vincent W.S. Wong2,6,7 & Henry L. Y. Chan2,6,7
We examined the global incidence and mortality rates of liver cancer, and evaluated the association 
between incidence/mortality and socioeconomic development (Human Development Index [HDI] 
and Gross Domestic Product [GDP]) using linear regression analysis. The average annual percent 
change (AAPC) of the trends was evaluated from join-point regression analysis. The global incidence 
of liver cancer varied widely by nine-fold, and was negatively correlated with HDI (men: r = −0.232, 
p = 0.003; women: r = −0.369, p < 0.001) and GDP per capita (men: r = −0.164, p = 0.036; women: 
r = −0.212, p = 0.007). Its mortality showed a similarly negative correlation with both indices. The 
greatest incidence rise in men was observed in Poland (AAPC = 17.5, 95% C.I. = 5.6, 30.9) and Brazil 
(AAPC = 13.2, 95% C.I. = 5.9, 21.0), whereas Germany (AAPC = 6.6, 95% C.I = 2.0, 11.5) and Norway 
(AAPC = 6.5, 95% C.I. = 3.2, 10.0) had the greatest increase in women. The mortality rates paralleled 
the incidence rates in most countries. For mortality, Malta (AAPC = 11.5, 95% C.I. = 3.9, 19.8), Australia 
(AAPC = 6.8, 95% C.I. = 2.2, 11.5) and Norway (APCC = 5.6, 95% C.I. = 2.8, 8.5) reported the biggest 
increase among men; whilst Australia (AAPC = 13.4, 95% C.I. = 7.8, 19.4) and Singapore (AAPC = 7.7, 
95% C.I. = 4.1, 11.5) showed the most prominent rise among women. These epidemiological data 
identified countries with potentially increasing trends of liver cancer for preventive actions.
Globally, liver cancer is the fifth commonest cancer in 2012, accounting for 9.1% of all cancer deaths worldwide1. 
The global disease burden attributable to this cancer induced a substantial number of years of life lost2. Owing 
to its extremely aggressive nature and poor survival rate3, it remains an important public health issue worldwide.
Most liver cancer (83%) was diagnosed in less well developed nations1. The vast majority (75–90%) of primary 
liver cancers are hepatocellular carcinomas (HCCs), with intrahepatic cholangiocarcinoma (ICC) accounting 
for most of the other cancer subtypes4. The recognized risk factors for HCC include chronic hepatitis B virus 
(HBV) and hepatitis C virus (HCV) infection, exposure to dietary aflatoxin, fatty liver disease, alcohol-induced 
cirrhosis, obesity, smoking, diabetes, and iron overload4–7. Two important risk factors for ICC include chronic 
liver fluke infestation and cirrhosis8,9 he former making ICC the most common subtype of liver cancer diagnosed 
in Thailand due to its high prevalence of liver fluke4.
Since a significant number of risk factors of liver cancer are modifiable, there is a strong prospect to reduce 
its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization10. 
Some of its etiological factors, including hepatitis infection and cirrhosis, are easily detectable by screening which 
can minimize development of liver cancer. Hence, it is crucial to understand its epidemiology with respect to 
its global pattern and trends. Previous studies describing the international trends of liver cancer were based on 
figures from registries in late 1990s to early 2000s; did not take into account the socioeconomic development of 
each country when comparisons were made; and depended on comparison among countries in a single calendar 
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year4,10,11. There have also been areas of controversy, including the differential effect of socioeconomic status on 
the risk of developing liver cancer as an important knowledge gap. Evaluating and analyzing the patterns and 
temporal trends of this cancer could quantify geographical variation, identify high-risk populations, delineate 
the extent of preventive strategies implemented, and might provide further insights into disease etiology. These 
epidemiological data could also be linked to the future prospects of cancer prevention and possibly screening 
strategies for policy-makers.
This study aims to delineate the patterns and temporal trends of liver cancer in as many countries as available, 
based on data from high quality cancer registries. We also tested the a priori hypothesis that the incidence and 
mortality of liver cancer, respectively, were associated with differences in socioeconomic development and pro-
ductivity across different countries.
Methods
Source of Data. The incidence and mortality estimates for liver cancer (ICD-10 C22) were retrieved from 
the GLOBOCAN database for 184 countries in 20121. We made reference to a recent analysis of epidemiological 
data on colorectal cancer and used similar methodology to evaluate the patterns and trends of liver cancer12,13. We 
obtained data on the Human Development Index (HDI) and Gross Domestic Product (GPD) for each country in 
2012 from the United Nations Human Development Report14. HDI is a composite index of life expectancy, edu-
cation period, and income per capita indicators, and is perceived as “an index of potential human development”14. 
To examine time trends, information was retrieved from different sources where at least 15 consecutive years 
of data could be obtained. We included data for countries where both incidence and mortality figures were 
available. For incidence figures, we extracted high-quality national population-based cancer registries from 
the Cancer Incidence in Five Continents (CI5) series Volumes I-X15. To include incidence data for more recent 
years, we also utilized publicly available information from the U.S.16, European countries17–19, Australia20 and 
the New Zealand21. The incidence data for liver cancer were allocated into different categories according to the 
International Classification of Diseases 10th revision (ICD-10 C22), whereas mortality data were categorized 
based on the ICD 9th (155) up to 1991 and 10th version (C22) thereafter22. When there are duplicates of incidence 
or mortality figures obtained from the CI5 and the regional registries, data from the national registries were used 
in the analysis as they provided more updated figures.
For mortality data, we made reference to the WHO mortality data series where data quality attained criteria of 
medium level or above23, which resulted in data with extensive coverage as well as high accuracy and complete-
ness. Death certificates acted as the primary data source, covering around 30% of the world population, and were 
compiled by the International Agency for Research on Cancer (IARC) as part of the WHO mortality database. 
We adopted age-standardized rate (ASR) using the world standard population24. Similar to the IARC, we defined 
more developed countries as all regions of Europe plus Northern America, Australia/New Zealand and Japan, 
and less developed regions as all regions of Africa, Asia (excluding Japan), Latin America and the Caribbean, 
Melanesia, Micronesia and Polynesia1. From these databases, there were a total of 38 countries where data were 
available for analysis of incidence and mortality trends.
Statistical Analysis. We employed joinpoint regression analysis to examine the incidence and mortality 
trends25, using the joinpoint statistical software version 3.4. This technique fits a series of joined straight lines 
to the trend of ASR25. Logarithmic transformation of the rates was performed with computation of the stand-
ard errors based on binomial approximation. We specified a maximum number of three joinpoints as analysis 
options, as in a previous similar study12. To determine the direction and magnitude of the recent trends, the 
average annual percent change (AAPC) and the respective 95% confidence intervals were evaluated for the last 
available 10 years. The AAPC was calculated as a geometrically weighted average of the various APCs from the 
joinpoint regression analysis, with weights being equivalent to the length of each segment during the specified 
time interval26. The statistical significance of AAPC was ascertained comparing its magnitude with zero, and all 
insignificant AAPCs were regarded as having “stable trend”.
The ASRs were plotted against the HDI and GDP per capita, respectively. The HDI was divided into four dis-
tinct categories, including low ( ≤ 0.534), medium (0.534 < HDI ≤ 0.710), high (0.710 < HDI ≤ 0.796) and very 
high (HDL > 0.796) based on the Human Development Report published in 201214. Simple linear regression and 
correlation coefficients were employed to examine their associations and the goodness-of-fit. All p values < 0.05 
were regarded as statistically significant.
Results
Incidence and mortality of liver cancer in 2012. A total of 782,451 new cases of liver cancer and 745,533 
related deaths were estimated in 2012 (Tables 1 and 2). Approximately 95% of the total incidence and 96% of all 
mortality occurred in less developed regions. The ratio between the ASR of incidence and mortality was higher 
in more developed countries than less developed ones in both male (1.21 vs. 1.05) and female (1.08 vs. 1.03). 
Among all continents, North America and Southern Europe had the highest incidence to mortality ratios. The 
incidence rates of liver cancer varied more than nine-fold worldwide in 2012. Among men, the highest were 
found in Eastern Asia (ASR 31.9 per 100,000), South-Eastern Asia (22.2), Northern Africa (18.0) and Western 
Africa (16.4), and the lowest were reported in South-Central Asia (3.7), Eastern Africa (4.9) and Western Asia 
(5.0) (Table 1). Among women, the highest were found in Eastern Asia (ASR 10.2 per 100,000), Western Africa 
(8.1), Melanesia (7.6) and South-Eastern Asia (7.2), and the lowest were reported in Micronesia/Polynesia (1.4), 
Northern Europe (1.8), Central and Eastern Europe (2.0) and South-Eastern Asia (2.1) (Table 2).
The mortality rates of liver cancer varied by more than eight-fold worldwide in 2012. In men, the highest 
death rates were reported in the Eastern Asia (29.9), South-Eastern Asia (21.4) and Northern Africa (17.4); whilst 
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in women, the highest mortality was also reported in these three regions (ASR mortality = 9.6, 6.8 and 7.7 per 
100,000, respectively). The lowest mortality rates were found in South-Central Asia (3.6), Northern Europe (4.0), 
and Eastern Africa (4.6) in men. For women, Northern Europe (1.8), Australia/New Zealand (2.0), Western 
Europe (2.1) and South-Central Asia (2.1) reported the lowest mortality rates. Countries having the highest inci-
dence to mortality ratios in men included North America (1.39), Southern Europe (1.27) and Western Europe 
(1.23), and the ratios were the highest for women in North America (1.17), Southern Europe (1.16) and Central 
America (1.08).
The relationship between incidence/mortality of liver cancer and socioeconomic development. 
The incidence of liver cancer decreased with higher levels of HDI in men (r2 = 0.054, r = − 0.232, p = 0.003) and 
women (r2 = 0.136, r = − 0.369, p < 0.001), and the same finding was observed for its correlation with GDP per 
capita (r2 = 0.0269, r = − 0.164, p = 0.036 and r2 = 0.0451, r = − 0.212, p = 0.007 for men and women, respec-
tively). For mortality, negative correlations with socioeconomic development were also observed for both HDI 
(r2 = 0.086, r = − 0.293, p < 0.001 for men and r2 = 0.14, r = − 0.375, p < 0.001 for women) and GDP per capita 
(r2 = 0.0359, r = − 0.189, p = 0.015 for men and r2 = 0.0470, r = − 0.217, p = 0.005 for women) (Figs 1a,b and 2a,b).
Trends in incidence and mortality from liver cancer. Supplementary Figure 1 depicts the temporal 
trends of incidence and mortality of liver cancer in 38 countries/regions according to gender and countries. 
Among men, there were a total of 14 countries with increasing incidence trends, 2 countries with decreasing inci-
dence, and 22 countries with stable incidence; whilst for women, there were 8 countries with increasing incidence, 
27 countries with stable incidence and 3 with decreasing incidence. For mortality, there were 12 countries with 
increasing trend, 8 countries with decreasing trend and 16 countries with stable mortality trends in men. There 
were 8 countries with increasing mortality, 8 countries with decreasing mortality and 20 countries with stable 
mortality in women. Supplementary Figures 2 and 3 shows the findings from the joinpoint regression analysis. 
We highlighted the countries with more prominent AAPCs according to the respective continents:
World regions
Population 
size, male 
(million)
Incidence Mortality
Incidence: 
mortality ration ASR n ASR
Africa 549,445 38,693 12.4 37,012 11.8 1.05
Eastern Africa 180,243 4,556 4.9 4,337 4.6 1.07
Middle Africa 69,179 3,669 10.5 3,469 9.9 1.06
Northern Africa 106,147 13,750 18 13,109 17.4 1.03
Southern Africa 29,735 1,359 6.7 1,295 6.7 1.00
Western Africa 164,141 15,359 16.4 14,802 15.6 1.05
Asia 2,179,003 430,690 20 407,700 18.9 1.06
Eastern Asia 813,296 342,180 31.9 322,903 29.9 1.07
South-Eastern Asia 305,225 58,453 22.2 55,827 21.4 1.04
South-Central Asia 933,786 25,805 3.7 24,927 3.6 1.03
Western Asia 126,697 4,252 5 4,043 4.9 1.02
America 303,514 40,288 7.4 34,704 6.2 1.19
Caribbean 20,951 1,420 6.1 1,421 6 1.02
Central America 82,227 4,720 6.9 4,508 6.6 1.05
South America 200,336 9,980 5.2 10,417 5.4 0.96
North America 173,209 24,168 9.3 18,358 6.7 1.39
Europe 355,275 42,814 6.8 39,926 6.1 1.11
Central and Eastern Europe 138,249 9,477 4.8 10,807 5.4 0.89
Northern Europe 49,574 4,203 4.6 3,897 4 1.15
Southern Europe 74,900 14,135 9.5 12,214 7.5 1.27
Western Europe 92,553 14,999 8 13,008 6.5 1.23
Oceania 18,859 1,884 7.8 1,699 7 1.11
Australia/New Zealand 13,632 1,385 6.4 1,212 5.4 1.19
Melanesia 4,628 450 14.8 433 14.4 1.03
Micronesia/Polynesia 258 49 9.1 54 10.1 0.90
More developed regions 604,008 92,018 8.6 80,425 7.1 1.21
Less developed regions 2,975,297 462,351 17.8 440,616 17 1.05
World 3,579,305 554,369 15.3 521,041 14.3 1.07
Table 1.  The estimated incidence and mortality of liver cancer according to world area, 2012, males. 
ASR = Age standardized rate per 100,000. Source: GLOBOCAN 2012 [1]. Numbers are rounded to the nearest 
10 or 100, and may not add up to the total. The population size of the world regions were retrieved from the 
Population Reference Bureau, Washington, DC. Available at: http://www.prb.org/Publications/Datasheets/2012/
world-population-data-sheet/world-map.aspx#/table/population.
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Latin America and the Caribbean. Brazil (AAPC = 13.2, 95% C.I. = 5.9, 21.0), Colombia (AAPC = 8.2, 95% 
C.I. = 2.5, 14.3) and Ecuador (AAPC = 5.9, 95% C.I. = 1.9, 10.0) showed an increase in incidence among men, 
whilst all countries had stable incidence trends in women (Fig. 3a). The ASRs of mortality reported an increase 
in Brazil (AAPC 0.9, 95% C.I. 0.4, 1.3) and decrease in Colombia in men (AAPC = − 2.8, 95% C.I. = − 4,0–1.7). 
Colombia (AAPC = − 3.6, 95% C.I. = − 4.6, − 2.5) and Ecuador (AAPC = − 2.7, 95% C.I. = − 4.6, − 0.8) had sig-
nificant reduction in mortality among women (Fig. 3b).
Northern America. An increase in incidence was observed in male (AAPC = 3.8, 95% C.I. = 2.2, 5.3) and female 
(AAPC = 2.1, 95% C.I. = 1.5, 2.8) Americans. A slight increase in mortality was reported in the US (AAPC = 3.1, 
95% C.I. = 2.7, 3.4 in men; AAPC = 2.3, 95% C.I. = 1.1, 3.5 in women) and Canada (AAPC = 2.2, 95% C.I. = 1.5, 
3.0 in men; AAPC = 1.9, 95% C.I. = 0.3, 3.6 in women).
Asia. China (AAPC = − 2.6, 95% C.I. = − 3.1, − 2.0) and Japan (AAPC = − 5.7, 95% C.I. = − 6.4, − 4.9) showed a 
reduction in incidence in men, and these two countries also reported a decline in women (China: AAPC = − 2.3, 
95% C.I. = − 3.2, − 1.4; Japan: AAPC = − 4.3, 95% C.I. = − 5.0, − 3.7). Thailand reported an increase in incidence 
in both men (AAPC = 6.4, 95% C.I. = 4.8, 8.1) and women (AAPC = 5.8, 95% C.I. = 2.7, 8.9). There was a sub-
stantial rise in mortality in the Singapore in women (AAPC = 7.7, 95% C.I. = 4.1, 11.5), whereas mortality rates 
in Japan dropped in both genders.
Oceania. There was a slight increase in incidence in Australia (AAPC = 5.5, 95% C.I. = 3.5, 7.6) among men, and 
Australia among women (AAPC = 4.4, 95% C.I. = 2.7, 6.2). Similarly for mortality, increases were also reported in 
Australia among men (AAPC = 6.8, 95% C.I. = 2.2, 11.5) and women (AAPC = 13.4, 95% C.I. = 7.8,19.4).
Northern Europe. Norway (AAPC = 7.2, 95% C.I. = 5.1, 9.3), Latvia (AAPC = 4.7, 95% C.I. = 2.6, 6.8), United 
Kingdom (AAPC = 4.4, 95% C.I. = 3.6, 5.2) and Denmark (AAPC = 3.7, 95% C.I. = 1.5, 5.9) were countries 
that reported an increase in incidence among men. Norway (AAPC = 6.5, 95% C.I. = 3.2, 10.0), Denmark 
World regions
Population size, 
female (million)
Incidence Mortality Incidence: 
mortality ration ASR n ASR
Africa 549,608 19,987 5.8 19,045 5.6 1.04
Eastern Africa 182,469 3,391 3.3 3,193 3.1 1.06
Middle Africa 69,644 2,139 5.7 2,046 5.4 1.06
Northern Africa 105,353 5,903 7 5,595 6.7 1.04
Southern Africa 30,816 873 3.3 832 3.2 1.03
Western Africa 161,327 7,681 8.1 7,379 7.7 1.05
Asia 2,081,150 163,741 6.9 159,186 6.6 1.05
Eastern Asia 777,374 124,156 10.2 121,045 9.6 1.06
South-Eastern Asia 306,008 21,500 7.2 20,530 6.8 1.06
South-Central Asia 881,514 15,582 2.1 15,161 2.1 1.00
Western Asia 116,253 2,503 2.6 2,450 2.5 1.04
America 310,360 22,872 3.4 23,180 3.3 1.03
Caribbean 21,313 1,204 4.5 1,218 4.4 1.02
Central America 83,632 5,082 6.6 4,837 6.1 1.08
South America 205,415 8,036 3.4 8,889 3.7 0.92
North America 176,585 8,550 2.7 8,236 2.3 1.17
Europe 381,747 20,648 2.2 22,265 2.2 1.00
Central and Eastern Europe 155,701 6,476 2 7,611 2.2 0.91
Northern Europe 51,252 2,254 1.8 2,418 1.8 1.00
Southern Europe 78,393 6,423 2.9 6,374 2.5 1.16
Western Europe 96,400 5,495 2.2 5,862 2.1 1.05
Oceania 18,746 834 3.1 816 2.9 1.07
Australia/New Zealand 13,715 569 2.1 562 2 1.05
Melanesia 4,451 256 7.6 241 7.3 1.04
Micronesia/Polynesia 580 9 1.4 13 2.2 0.64
More developed regions 637,294 42,284 2.7 42,652 2.5 1.08
Less developed regions 2,880,901 185,798 6.6 181,840 6.4 1.03
World 3,518,195 228,082 5.4 224,492 5.1 1.06
Table 2.  The estimated incidence and mortality of liver cancer according to world area, 2012, females. 
ASR = Age standardized rate per 100,000. Source: GLOBOCAN 2012 [1]. Numbers are rounded to the nearest 
10 or 100, and may not add up to the total. The population size of the world regions were retrieved from the 
Population Reference Bureau, Washington, DC. Available at: http://www.prb.org/Publications/Datasheets/2012/
world-population-data-sheet/world-map.aspx#/table/population.
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(AAPC = 4,0 95% C.I. = 0.3, 7.8) and United Kingdom (AAPC = 2.4, 95% C.I. = 0.9, 3.9) had incidence increase 
among women. Norway (AAPC = 5.6, 95% C.I. = 2.8, 8.5), the United Kingdom (AAPC = 4.7, 95% C.I. = 3.6, 5.8) 
and Lithuania (AAPC = 2.5, 95% C.I. = 0.8, 4.3) reported increase in mortality among men, and the former two 
also showed an increase in mortality among women.
Western Europe. Switzerland showed an increase in incidence among men (AAPC = 4.2, 95% C.I. = 1.6, 6.9) 
and Germany reported increase in incidence in women (AAPC = 6.6, 95% C.I. = 2.0, 11.5). The Netherlands 
showed an increase in mortality in men (AAPC = 2.0, 95% C.I. = 0.7, 3.3), and Germany reported an increase in 
mortality among men (AAPC = 0.9, 95% C.I. = 0.3, 1.5) and women (AAPC = 0.7, 95% C.I. = 0.1, 1.3).
Southern Europe. Slovenia (AAPC = 3.1, 95% C.I. = 0.9, 5.3) was the only country that reported rise in inci-
dence among men, whilst Croatia showed a decline in incidence among women (AAPC = − 2.9, 95% C.I. = − 
5.1, − 0.6). Malta (AAPC = 11.5, 95% C.I. = 3.9, 19.8), Slovenia (AAPC = 2.6, 95% C.I. = 1.1, 4.1) and Croatia 
(AAPC = 2.4, 95% C.I. = 0.9, 3.9) reported increase in mortality in men.
Eastern Europe. The incidence trends in men and women were all stable, whilst the majority of countries in this 
continent reported a decline in mortality in both men and women.
Discussion
Summary of the Major Findings. This study presented a comprehensive epidemiological analysis of the 
global profiles of liver cancer incidence and mortality based on high quality data. Geographical variations in its 
incidence and mortality were substantial - both between and within continents. As of 2012, Eastern Asia, South-
Eastern Asia and Northern Africa suffered from the highest incidence in both genders and highest mortality in 
women. Eastern Asia, Western Africa and Melanesia reported the highest mortality in men. The highest incidence 
to mortality ratio was found in Northern America and Southern Europe for both men and women. It was found 
that countries with higher levels of HDI and GDP per capita reported lower incidence and mortality rates of 
liver cancer. Taking into account the average change of incidence in the previous 10 years, the most remarkable 
observation included the increase in incidence in Brazil, Colombia and Thailand in men, as well as Brazil and 
Germany in women. There were rises in mortality rates in Malta, Norway and the United Kingdom in men, and 
Figure 1. (a) Correlation between age-standardised incidence of liver cancer and Human Development Index 
(HDI) in men (left) and women (right); (b). Correlation between age-standardised incidence of liver cancer and 
Gross Domestic Product (GDP) per capita in men (left) and women (right).
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very substantial increase in mortality in Singapore and Denmark in women. Irrespective of gender, a substantial 
reduction in mortality rate was observed for Japan and Czech Republic. Most countries included in the analysis 
presented insignificant changes in incidence and mortality trends, with relatively wide 95% confidence intervals.
The results from this study in general corroborated the findings of previous observations27,28 - where the 
incidence and mortality were increasing in countries with low incidence of liver cancer, such as Latin America 
(Brazil), Northern Europe (Norway, UK, Denmark) and Western Europe (Germany). As highlighted by Torre and 
colleagues, this phenomenon has been attributed to an increase in prevalence of HCV infection in some countries 
due to injection drug abuse in the 1960s to 1970s28. Some studies suggested that escalating rates of obesity and 
type II diabetes in these relatively well developed countries may be contributory3,29. On the other hand, the inci-
dence and mortality rates of liver cancer were found to be declining in countries that had higher incidence, such 
as Japan and China. This observation has been explained by the reduction in aflatoxin exposure and infection 
with HBV in China due to immunization and other population-based cancer prevention programmes30,31. The 
lower incidence rates in Japan could be attributed to reduction in chronic schistosomiasis infection, as well as 
HCV infection via more hygienic blood donation practices and implementation of policies that deterred intrave-
nous drug use30,32. Other factors that might change the incidence and mortality of liver cancer include the formu-
lation of country-specific preventive strategies, like reinforcement of lifestyle changes (e.g. smoking and alcohol 
drinking); community-based health promotion initiatives (e.g. prevention of liver fluke infestations from water 
sources via education; needle exchange programmes for intravenous drug users); environmental modifications 
(e.g. improving storage of grains and crop substitution to prevent aflatoxin contamination); and improved med-
ical interventions (e.g. new antiviral therapies for those with acute HCV and chronic HBV or HCV infections; 
drug treatment for liver fluke)27,33–35.
We found that countries with higher HDI and GDP per capita had lower incidence and mortality of liver cancer 
from correlation analysis. Apart from racial and ethnic differences, lower socioeconomic status and poverty have 
been associated with risk factors for HCC, including diabetes36, metabolic syndrome37, obesity38, alcoholism39, 
HBV40, and HCV infection41–43. In addition, lower educational attainment has been linked to higher risk of viral 
hepatitis infection, alcoholism and hepatic inflammation44. Changes in some of these risk factors such as alcohol 
drinking per capita, HDI and GDP per capita might potentially influence the AAPC in each country, and future 
studies should explore their interrelationships.
Figure 2. (a) Correlation between age-standardised mortality of liver cancer and Human Development Index 
(HDI) in men (left) and women (right); (b). Correlation between age-standardised mortality of liver cancer and 
Gross Domestic Product (GDP) per capita in men (left) and women (right).
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Figure 3. (a) The Average Annual Percent Change (AAPC) of liver cancer incidence in men (left) and women 
(right) in the most recent 10 years; (b). The Average Annual Percent Change (AAPC) of liver cancer mortality in 
men (left) and women (right) in the most recent 10 years.
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This study is the first evaluation of the incidence and mortality trends of liver cancer on a global scale. It pre-
sented and analyzed the most up-to-date epidemiological data on this important cancer, and quantified the geo-
graphical variations as well as trends in its incidence and mortality using data of high validity, completeness and 
comparability. We also adopted figures on national mortality that fulfilled criteria attaining at least WHO-defined 
medium levels of coverage and completeness. The IARCs estimation methods have been further refined in more 
recent years to take into account the increasing availability and quality of the source data45. Nevertheless, some 
limitations should be addressed. Firstly, failure or under-reporting of cancer diagnosis could lead to bias in cancer 
registration especially in relatively less-developed nations. Figures in regional cancer registries could be under-
estimated owing to limited local facilities. On the contrary, in countries where estimates were based on a single 
cancer registry in more urbanized, resource privileged areas, the presented figures could be an overestimation 
if the countries consist of extensive rural populations. In addition, only one-third and one-fifth of the world’s 
countries, respectively, reported incidence and mortality data of high quality. As a result, the incidence and mor-
tality data are constrained with respect to geographical coverage, in particular the resource-deprived countries. 
It should be noted that the correlation coefficients are not high (ranging from − 0.189 to − 0.315), and cautions 
are needed in interpreting the correlation between HDI/GDP and incidence/mortality rates. Lastly, ecological 
fallacy is an inherent limitation of the present study, where correlations performed in this analysis were derived 
from group variables.
The incidence and mortality rates of liver cancer increased in many countries that had low rates, although 
a few countries used to have high rates reported declining incidence trends. Future studies should explore the 
underlying reasons for these epidemiological trends, which could offer further insights into the specific etiologi-
cal factors of liver cancer. In addition, the impact of socioeconomic development on the incidence and mortality 
of liver cancer is of interest, and should be evaluated in future longitudinal studies.
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